ISRCTN58863784已完成未知
DEveloping Tests for Endometrial Cancer deTection
Manchester University Hospital NHS Foundation Trust0 个研究点目标入组 1,890 人开始时间: 2018年8月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,890
研究概览
简要总结
2021 Protocol article in http://dx.doi.org/10.1136/bmjopen-2021-050755 (added 21/09/2021)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Women with unexplained postmenopausal bleeding attending for urgent investigations to exclude endometrial cancer
- •2. Written informed consent to participate
排除标准
- •Current exclusion criteria as of 21/12/2018:
- •1. Abnormal bleeding before the menopause (in whom the risk of cancer is much lower)
- •2. Previous diagnosis of endometrial cancer
- •3. Previous hysterectomy
- •4. Mirena coil in situ or removed within the last 3 months
- •5. Any other condition that would compromise participant safety or data integrity
- •Previous exclusion criteria:
- •1. Abnormal bleeding before the menopause (in whom the risk of cancer is much lower)
- •2. Previous diagnosis of endometrial cancer
- •3. Previous hysterectomy
研究者
相似试验
招募中
不适用
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in TamponsEndometrial CancerEndometrial Cancer PrecursorsComplex Atypical Endometrial HyperplasiaOvarian CancerNCT03538665University of Alabama at Birmingham1,700
已完成
不适用
Development of a Molecular Diagnostic Tool for Endometrial Cancer.Endometrium CancerNCT06192017MiMARK Diagnostics, S.L.1,950
Unknown
不适用
Biomarkers for Diagnosis and Prognosis of Endometrial CarcinomaEndometrial CancerNCT03553589Andrea Romano400
招募中
不适用
Non-Invasive Diagnosis of Endometrial CancerEndometrial CancerNCT05737797Assistance Publique - Hôpitaux de Paris100
撤回
1 期
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerEndometrial CancerNCT06385548Vall d'Hebron Institute of Oncology15